News

Kisspeptin Benefits: What Human Studies Found

Creator: Julian Reyes, Health Writer
Published: 2026-09-08

In people, kisspeptin has done two things reliably: switched on the reproductive hormone system, and changed how the brain handles sexual cues. Nearly all of it was measured over hours, in a hospital.

Julian Reyes, Health Writer September 8, 2026 6 min read

A man in a charcoal long-sleeve top and olive trousers walks toward the camera along a dirt path through open grassland

The short version

Human studies show kisspeptin doing two things reliably: raising the pituitary hormones LH and FSH, with testosterone following in men, and changing brain activity in response to sexual cues. Both were measured over hours, not months.
In the two low-desire trials, 32 women and 32 men completed a single 75-minute infusion each. Brain activity in the sexual-processing network shifted against placebo (in the men, Cohen d 0.81), and the men's erectile response during the scan ran up to 56% higher. Both trials reported no adverse events.
Kisspeptin-10 clears fast — a half-life of 3.8 minutes in men and 4.1 in women, against about 27 minutes for the long form — so route and timing dominate every discussion of how it is used.
An August 2026 study in 15 healthy men found continuous dosing lost the hormone response within five days, while an eight-hours-on, sixteen-hours-off pattern kept LH raised for 12 days with the receptor still responding.
Kisspeptin dispensed through Promise is a compounded medication and is not FDA-approved; compounded medications are not reviewed by the FDA for safety, effectiveness, or quality. A licensed provider decides whether to prescribe it.
Nothing published in people shows kisspeptin causing weight loss, muscle gain, better sleep, or slower ageing.

The honest answer about kisspeptin benefits is that they're narrow, specific, and almost all measured over a few hours in a hospital research unit. Two things happen reliably. Give a healthy man kisspeptin and the two pituitary signals that drive the testes — LH and FSH — climb, and testosterone follows. Give it to someone distressed by low sexual desire and the parts of the brain that handle sexual cues respond differently than they do on placebo. That's the list. Nothing published shows it burning fat, building muscle, or lifting mood for weeks on end.

That narrowness isn't a knock on the compound. It's a description of how far the research has got. Kisspeptin sits above the reproductive hormone system rather than inside it — what does kisspeptin do walks through that cascade — and nearly everything published measures a few hours of hormone release, not months of how someone feels.

Which kisspeptin benefits have actually been measured

The first human study is still one of the clearest. Six healthy men were given a 90-minute drip of kisspeptin-54, the full-length form of the peptide, and LH, FSH and testosterone all rose (Dhillo 2005, JCEM 90(12):6609–15).

Then it got more interesting, and more complicated. A later study at Imperial College London gave the short form, kisspeptin-10, to healthy men and women. In men, LH and FSH climbed after doses as small as 0.3 nmol/kg. In women during the first half of the menstrual cycle, nothing moved at all — not into a vein, not under the skin, not by slow infusion. Women closer to ovulation did respond (Jayasena 2011, JCEM 96(12):E1963–72).

That result is worth sitting with, because no seller's page will tell you about it. Same compound, same doses, a clear response in men and nothing in half the menstrual cycle. Whatever kisspeptin does, it does through a system with its own timing, and it can only flip a switch that's ready to be flipped.

The brain studies are why people got interested

In 2017, 29 healthy young men each had two visits — one with kisspeptin, one with a dummy infusion, neither they nor the researchers knowing which was which — and had their brains scanned while they looked at sexual and couple-bonding images. On kisspeptin, the emotional centres of the brain lit up more for those images specifically, and the men reported less negative mood afterwards (Comninos 2017, J Clin Invest 127(2):709–19).

Two later trials took it to people who actually had the problem. Both enrolled adults with hypoactive sexual desire disorder — persistently low desire that genuinely bothers the person — and both used a single 75-minute infusion against a matched placebo.

In the women's trial, 40 were randomised and 32 completed both visits. Kisspeptin shifted activity in the regions that process erotic material and faces, and the size of that shift tracked with how distressed a woman was about her desire to begin with (Thurston 2022, JAMA Netw Open 5(10):e2236131). In the men's trial, 37 were randomised and 32 finished. Brain activity across the sexual-processing network moved against placebo by a moderate-to-large margin (Cohen d 0.81; 95% CI, 0.41–1.21; P = .003), and erectile response measured during the scan ran up to 56% higher than on placebo (Mills 2023, JAMA Netw Open 6(2):e2254313). Both papers report that kisspeptin was well tolerated with no adverse events.

Hold on to two things there. These were single infusions given in a hospital over roughly an hour, using the long form of the peptide. And what was measured was brain activity — a plausible early step, not a change in anyone's life over months.

If low desire is the real question, PT-141 is the compound most people end up weighing against it. It acts on a different receptor system further down the chain and has been through larger trials aimed at desire itself rather than at brain scans.

Four minutes is the practical catch

The same 2011 study timed how fast kisspeptin-10 leaves the blood. Its half-life — how long the body takes to clear half of what's circulating — was 3.8 minutes in men and 4.1 minutes in women. The long form, kisspeptin-54, lasts about 27 minutes.

Four minutes is very short for a medicine. It means the shape of a dose matters more than its size, which is why serious discussion of this compound is about route and rhythm, not milligrams. Kisspeptin-10 goes into the fragment itself in more detail.

What the newest study found

As of September 6, 2026, the day this article was written, the most recent human kisspeptin study was published on August 3, and it went straight at the question that matters most: does it keep working?

Researchers gave kisspeptin-10 under the skin to 15 healthy men, in three parts — a dose-finding session, five days of continuous infusion, and then twelve days of eight hours on and sixteen hours off. Running it continuously stopped paying: after five days, testosterone was still up but LH and FSH had fallen back to no different from the dummy infusion. The on-off pattern held. LH was still raised on day 12, and a test dose at the end still produced a response, meaning the receptor hadn't switched itself off (Yeung 2026, Eur J Endocrinol 195(2):206–16).

Fifteen healthy volunteers is physiology, not a treatment trial; the authors describe it as working out a protocol. It is still the first human evidence that repeated dosing can hold up when the timing is right — and that the wrong timing quietly stops working while you're still taking it.

Where it stands with regulators

There is no FDA-approved kisspeptin product, here or anywhere. Kisspeptin dispensed through Promise is a compounded medication, prepared by a licensed U.S. pharmacy against a prescription written for one person, and it is not FDA-approved. Compounded medications are not reviewed by the FDA for safety, effectiveness, or quality.

One more piece of the regulatory picture is worth knowing. The FDA sorts the ingredients pharmacies have put forward for compounding into three groups, and kisspeptin-10 sits in the second — substances the agency says raise significant safety concerns. Its stated reason isn't that harm was seen. It's that a peptide like this may carry a risk of provoking an immune response by some routes, that impurities and chemical characterisation are complicated, and that the agency has "no, or only limited, safety-related information" for the routes proposed (FDA, certain bulk drug substances that may present significant safety risks). As of September 6, 2026, the day this article was written, kisspeptin-10 was still in that group on the nominations list the FDA last updated on May 14, 2026.

None of that makes kisspeptin unavailable or unlawful. It means the evidence is thin, and thin evidence is an argument for a clinician in the room rather than a forum thread. A licensed provider reviews your history and either writes the prescription or declines — and people are declined.

What kisspeptin hasn't been shown to do

No published human trial shows kisspeptin causing weight loss, muscle gain, better sleep, or slower ageing. It isn't testosterone and it isn't a replacement for it; it works by asking your own system to make more, which means it needs a system capable of answering. It hasn't been studied in anyone for months at a stretch. And the desire trials measured brain activity and, in the men, erectile response — not a lasting change in a relationship.

That's the trade: an unusually well-mapped mechanism, a short and small human record, and a compound whose timing seems to decide whether it does anything at all. If you're weighing it up, how to get prescribed peptides covers what the visit actually involves.

Common questions

What are the main kisspeptin benefits found in human studies?

Two, and both are narrow. Kisspeptin raises the pituitary hormones LH and FSH and, in men, testosterone with them. And in brain-scan trials it changed how the brain responded to sexual and bonding cues, including in men and women with persistently low desire. Every one of those studies gave a single infusion in a hospital and measured hours, not months.

Is kisspeptin FDA-approved?

No. There is no FDA-approved kisspeptin product in the United States or anywhere else. What a licensed pharmacy can prepare is a compounded medication, made against a prescription written for one person, and compounded medications are not reviewed by the FDA for safety, effectiveness, or quality. A licensed provider decides whether prescribing it is appropriate, and may decline.

How long does kisspeptin stay in the body?

Not long. Kisspeptin-10, the short form, was cleared with a half-life of 3.8 minutes in men and 4.1 minutes in women in a 2011 study at Imperial College London. The full-length form, kisspeptin-54, lasts around 27 minutes. Both are brief enough that how and when a dose is given matters more than how large it is.

Does kisspeptin work the same way in men and women?

No, and that is one of the more useful findings in the literature. In the 2011 study, kisspeptin-10 raised LH and FSH in healthy men at low doses but moved nothing at all in women during the first half of the menstrual cycle, by any route tried. The same women responded closer to ovulation. The underlying hormone system's timing decides the result.

Is kisspeptin the same as PT-141?

They are different molecules working at different points. Kisspeptin acts at the top of the reproductive hormone chain, on the neurons that start the whole cascade. PT-141 acts on a separate receptor family in the brain and has been studied against desire outcomes directly rather than against brain-scan measures. People considering one often look at both.

What did the 2026 kisspeptin study add?

It tested whether repeated dosing keeps working. In 15 healthy men, five days of continuous kisspeptin-10 lost the hormone response, while eight hours on and sixteen hours off held LH raised through day 12 with the receptor still responding. It was a small physiology study designed to work out a protocol, not a trial of any treatment.